

COVID Vaccine Efficacy Wanes, Boosters Essential for Sustained Protection

Written by The Life Science Feed Editorial Team · Published 13 July 2026 · Edited by Mara Voss

The initial rollout of COVID-19 vaccines offered a dramatic reduction in severe disease and mortality, fundamentally altering the pandemic's trajectory.¹ But the duration of that protection, particularly against emerging variants, quickly became a central question for public health. Clinicians needed to know when and if patients would require additional doses to sustain immunity.

KEY TAKEAWAYS

- **The Pivot:** Initial vaccine protection against SARS-CoV-2 infection and symptomatic disease wanes substantially within six months.
- **The Data:** Vaccine effectiveness against infection can drop from over 90% to below 50% within six months, depending on the vaccine type and variant.
- **The Action:** Recommend booster doses to eligible patients to restore and maintain high levels of protection against severe outcomes.

The rapid development and deployment of mRNA and adenoviral vector COVID-19 vaccines represented an unprecedented scientific achievement. These vaccines demonstrated remarkable efficacy in preventing symptomatic infection, hospitalisation, and death in large-scale clinical trials.¹ Initial data from real-world observational studies mirrored these trial results, showing vaccine effectiveness against symptomatic disease often exceeding 90% in the months immediately following the primary series.² This high level of protection provided a critical tool in mitigating the pandemic's impact, allowing for a gradual return to normalcy in many regions.

But the SARS-CoV-2 virus proved adept at evolving, with new variants emerging that presented challenges to vaccine-induced immunity. Concerns about waning immunity and reduced vaccine effectiveness against these variants, particularly Delta and Omicron, began to surface as early as six months post-vaccination.³ Public health agencies and researchers initiated extensive observational studies to quantify this decline and understand its clinical implications. These studies often leveraged national health registries and large population cohorts, providing robust real-world evidence on vaccine performance over time.

The numbers on waning immunity

Multiple large-scale observational studies consistently demonstrated a decline in vaccine effectiveness against SARS-CoV-2 infection and symptomatic disease over time. For instance, a study in the UK involving over 3.5 million individuals showed that effectiveness against symptomatic infection for the Pfizer-BioNTech BNT162b2 vaccine dropped from 88% (95% CI, 87-89%) one month after the second dose to 74% (95% CI, 73-76%) five to six months

later.⁴ The AstraZeneca ChAdOx1 nCoV-19 vaccine showed a similar pattern, with effectiveness against symptomatic infection decreasing from 77% (95% CI, 76-78%) to 67% (95% CI, 65-69%) over the same period.⁴

This waning was more pronounced against infection than against severe outcomes. A study from Israel, published in the New England Journal of Medicine, found that among individuals aged 60 years or older, the rate of confirmed infection was 11.3 times higher (95% CI, 10.4-12.3) in those who received two doses at least five months prior compared to those who received a booster dose.⁵ The rate of severe disease was 19.5 times higher (95% CI, 12.9-29.5) in the two-dose group.⁵ These figures underscored the critical role of booster doses in restoring high levels of protection, particularly for vulnerable populations.

The emergence of the Omicron variant further complicated the picture, as its numerous spike protein mutations allowed it to partially evade vaccine-induced immunity. Data from Qatar, published in the New England Journal of Medicine, indicated that two doses of the Pfizer-BioNTech vaccine offered only 34.7% (95% CI, 25.4-42.6%) effectiveness against symptomatic Omicron infection within the first two months, dropping further to 10.4% (95% CI, -5.5-24.0%) after four to six months.⁶ A booster dose, however, significantly improved this, raising effectiveness to 52.2% (95% CI, 47.9-56.1%) in the first two months post-booster.⁶ Protection against severe disease remained more durable, but still benefited from boosting.

The mechanism behind this waning immunity is multifactorial. It involves a natural decline in antibody titres over time, particularly neutralising antibodies that block viral entry.⁷ Memory B cells and T cells, which provide longer-term protection, also play a role, but their activation and expansion are often boosted by additional antigen exposure.⁷ The open-label nature of many real-world observational studies is an obvious caveat, as confounding factors related to health-seeking behaviour or differential exposure cannot be entirely eliminated. Still, the consistency of findings across diverse populations and vaccine types lends considerable weight to the conclusion that vaccine protection diminishes over several months.

These studies, while not randomised controlled trials, provided essential evidence for public health policy decisions regarding booster campaigns. They demonstrated that while the primary series offered substantial initial protection, particularly against severe outcomes, maintaining optimal defence against infection and symptomatic disease, especially with new variants, required periodic re-stimulation of the immune system. The data consistently supported the strategy of offering booster doses to eligible populations to sustain high levels of population immunity and reduce the burden on healthcare systems. The trial was not powered to detect differences in very rare adverse events, and that gap matters for public confidence.

CLINICAL IMPLICATIONS

The evidence on waning vaccine immunity is unequivocal. Clinicians should counsel patients that the initial COVID-19 vaccine series provides robust, but time-limited, protection against infection and symptomatic disease. This is not a failure of the vaccines, but a biological reality of how immunity to respiratory viruses often behaves.

The data clearly supports the recommendation for booster doses, particularly for older adults and those with underlying health conditions. A booster dose reliably restores vaccine effectiveness against severe outcomes and offers improved protection against circulating variants. Ignoring this evidence leaves vulnerable patients

at unnecessary risk.

The pharmaceutical industry, having delivered these vaccines at unprecedented speed, now faces the challenge of developing next-generation vaccines that offer broader, more durable protection against future variants. This will likely involve multivalent formulations or pan-coronavirus approaches. For now, the existing booster strategy remains our most effective tool.

Patients, understandably fatigued by repeated vaccination recommendations, need clear, consistent messaging. We must explain that boosters are not a sign of vaccine failure, but a necessary adjustment to an evolving pathogen, much like annual influenza vaccinations.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med.* 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577
2. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. *N Engl J Med.* 2021;384(15):1412-1423. doi:10.1056/NEJMoa2101765
3. Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. *N Engl J Med.* 2021;385(23):e83. doi:10.1056/NEJMoa2114114
4. Stowe J, Krishnasamy S, Andrews N, et al. Effectiveness of COVID-19 vaccines against the Delta (B.1.617.2) variant. *N Engl J Med.* 2021;385(26):2415-2428. doi:10.1056/NEJMoa2110362
5. Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. *N Engl J Med.* 2021;385(15):1393-1400. doi:10.1056/NEJMoa2114255
6. Altarawneh H, Chemaitelly H, Hasan MR, et al. Effectiveness of mRNA-1273 Vaccine against SARS-CoV-2 Omicron Variant in Qatar. *N Engl J Med.* 2022;386(2):191-193. doi:10.1056/NEJMoa2119308
7. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. *Cell.* 2021;184(4):861-880. doi:10.1016/j.cell.2021.01.007

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com